In the world of thriller novels, suspense and adrenaline-fueled action sequences take centerstage, keeping readers on the edge of their seats with each turn of the page. However, amid the fast-paced ...

NEWARK, CA / ACCESSWIRE / October 9, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that the company will be eligible to receive $60M in milestone ...

The University of Delaware is set to host the inaugural UD Convening on Character Development on Friday, Feb. 7, 2025, from 9 a.m. to 4 p.m. at the Audion in the Tower at STAR. This event aims to ...

Protagonist Therapeutics (PTGX) announced the selection of PN-881, an oral peptide interleukin-17, or IL-17, antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (PTGX) ("Protagonist" or the "Company") today announced the selection of PN-477, a potential best-in-class GLP-1, ...

NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, ...

Takeda Pharmaceutical Co. Ltd. and Protagonist Therapeutics Inc. have inked a global development and commercialization deal worth up to $1.7 billion for Protagonist’s rusfertide for treatment of ...

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I ...

Protagonist Pictures has upped Alice Vail to head of acquisitions and development alongside a series of key internal promotions across various department and a new addition to its team. Previously ...